ACM
URGN icon

Aquatic Capital Management’s UroGen Pharma URGN Stock Holding History

Aquatic Capital Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,627
Closed -$40.1K – 1566
2025
Q1 		$40.1K Sell
3,627
-5,819
-62% -$62K ﹤0.01% 1151
2024
Q4 		$101K Buy
+9,446
New +$113K ﹤0.01% 1066
2022
Q1 		– Sell
-6,410
Closed -$61K – 1556
2021
Q4 		$61K Buy
+6,410
New +$90.4K 0.12% 256

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Aquatic Capital Management's URGN Position: Q2 2025 in Review

Aquatic Capital Management sold out of UroGen Pharma (URGN) in Q2 2025, closing a stake of 3,627 shares — an estimated $40.1K sold.

Aquatic Capital Management first reported a position in URGN in Q4 2021 and held it in 3 quarters. The position peaked at $101K in Q4 2024. 150 funds tracked by Wall St. Rank hold URGN as of Q2 2025.

  • Aquatic Capital Management reported no remaining UroGen Pharma position as of Q2 2025 after selling out during the quarter.
  • Aquatic Capital Management sold 3,627 UroGen Pharma shares in Q2 2025, an estimated $40.1K.
  • Aquatic Capital Management first reported a position in UroGen Pharma in Q4 2021 and held it in 3 quarters.
  • Aquatic Capital Management's UroGen Pharma position peaked at $101K in Q4 2024.
  • 150 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2025.

Based on Aquatic Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.